NBY Stock NovaBay Pharmaceuticals (NBY, $0.12) RSI Indicator left the overbought zone on May 16, 2024

GET DAILY SIGNALS

Get AI intraday signals

NBY - NovaBay Pharmaceuticals

RSI signal

View

Odds of DOWN Trend

Price: $0.12

Daily change: +$0.0155 (+14.83%)

Daily volume: 32.5M

Capitalization: $4.5M

Industry: Biotechnology

NBY's RSI Oscillator recovers from overbought zone

The 10-day RSI Oscillator for NBY moved out of overbought territory on October 31, 2024. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 18 instances where the indicator moved out of the overbought zone. In of the 18 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 31 cases where NBY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

NBY broke above its upper Bollinger Band on October 30, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for NBY entered a downward trend on October 29, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 14, 2024. You may want to consider a long position or call options on NBY as a result. In of 74 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for NBY just turned positive on October 30, 2024. Looking at past instances where NBY's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

NBY moved above its 50-day moving average on October 29, 2024 date and that indicates a change from a downward trend to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where NBY advanced for three days, in of 218 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.332) is normal, around the industry mean (14.655). P/E Ratio (0.000) is within average values for comparable stocks, (96.848). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.824). NBY has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (0.076) is also within normal values, averaging (218.428).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. NBY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NBY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.